STipe Therapeutics appoints Dr Natalie Sacks as Independent Board Member and Dr Richard Bethell as Chief Development Officer16. April 2020|In Portfolio News|By eazee-designstudioSTipe Therapeutics announced the appointment of seasoned industry experts: “Both Natalie and Richard are highly experienced industry executives who bring a wealth of international drug development and approval expertise to STipe,” said Dr Claus Elsborg Olesen (CEO). “We are developing novel cancer therapies and I look forward to drawing on their extensive experience as we prepare for the selection of a lead candidate for clinical development.” PrevNext
